<DOC>
	<DOCNO>NCT00001022</DOCNO>
	<brief_summary>Primary : To compare efficacy zidovudine ( AZT ) give alone versus AZT plus didanosine ( ddI ) versus AZT plus zalcitabine ( dideoxycytidine ; ddC ) delay occurrence AIDS-related condition HIV-infected patient . Secondary : To compare frequency severity adverse experience three regimen . To compare mortality rate three regimen . To compare effect antiretroviral regimen CD4+ cell level . Studies indicate maintenance therapy AZT extend period may limit dose-dependent toxicity , primarily myelosuppression , emergence drug-resistant HIV strain . It anticipate combination AZT either ddI ddC may promote high antiviral efficacy , acceptable toxicity less likelihood development drug-resistant strain , AZT alone .</brief_summary>
	<brief_title>A Comparison Zidovudine ( AZT ) Used Alone Combination With Didanosine ( ddI ) Dideoxycytidine ( ddC ) HIV-Infected Patients</brief_title>
	<detailed_description>Studies indicate maintenance therapy AZT extend period may limit dose-dependent toxicity , primarily myelosuppression , emergence drug-resistant HIV strain . It anticipate combination AZT either ddI ddC may promote high antiviral efficacy , acceptable toxicity less likelihood development drug-resistant strain , AZT alone . Approximately 1200 patient randomize 2:1:1:2 ratio one follow four treatment arm : AZT plus ddI , AZT plus ddI placebo , AZT plus ddC placebo , AZT plus ddC . Average follow-up 2 year .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Required : Documented HIV infection OR work diagnosis HIV OR evidence idiopathic suppression AIDSdefining opportunistic infection malignancy ( except Kaposi 's sarcoma ) . CD4+ cell count = &lt; 200/mm3 = &lt; 15 percent total lymphocyte count within previous 90 day OR history AIDSdefining opportunistic infection . Current PCP prophylaxis . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Symptoms pancreatitis peripheral neuropathy grade 2 worse . Requirement acute therapy active AIDSdefining opportunistic infection systemic chemotherapy malignancy . Stage 2 worse ( moderate ) AIDS Dementia Complex . Other disorder condition study drug contraindicate may prevent adequate compliance study therapy . Concurrent Medication : Excluded : Acute therapy active AIDSdefining opportunistic infection . Systemic chemotherapy malignancy . Antiretroviral therapy provide study . Patients follow prior condition exclude : History pancreatitis peripheral neuropathy grade 2 worse . History intolerance study drug entry dos and/or frequency . History phenylketonuria .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>